This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ghosn, J.
Right arrow Articles by Tubiana, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ghosn, J.
Right arrow Articles by Tubiana, R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2008, p. 1542-1544, Vol. 52, No. 4
0066-4804/08/$08.00+0     doi:10.1128/AAC.01301-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Antiretroviral Therapy with a Twice-Daily Regimen Containing 400 Milligrams of Indinavir and 100 Milligrams of Ritonavir in Human Immunodeficiency Virus Type 1-Infected Women during Pregnancy{triangledown}

Jade Ghosn,1* Ines De Montgolfier,2 Chantal Cornélie,3 Stéphanie Dominguez,1 Claire Pérot,2 Gilles Peytavin,4 Anne-Geneviève Marcelin,5 Michèle Pauchard,1 Zineb Ouagari,1 Manuela Bonmarchand,6 Rachid Agher,1 Vincent Calvez,5 François Bricaire,1 Marc Dommergues,3 Christine Katlama,1 and Roland Tubiana1

AP-HP, Department of Infectious Diseases, Pitié-Salpétrière Hospital, Paris, France,1 AP-HP, Department of Neonatology, Pitié-Salpétrière Hospital, Paris, France,2 AP-HP, Department of Gynecology and Obstetrics, Pitié-Salpétrière Hospital, Paris, France,3 AP-HP, Department of Clinical Pharmacology, Bichat-Claude Bernard Hospital, Paris, France,4 AP-HP, Department of Virology, Pitié-Salpétrière Hospital, Paris, France,5 AP-HP, Department of Internal Medicine, Pitié-Salpétrière Hospital, Paris, France6

Received 9 October 2007/ Returned for modification 30 November 2007/ Accepted 28 January 2008

We evaluated the safety and efficacy of a twice daily regimen containing 400 mg of indinavir and 100 mg of ritonavir in 32 human immunodeficiency virus (HIV)-infected women during pregnancy. The median indinavir trough concentration was 208 ng/ml during the third trimester. At delivery, 26 of 28 women on indinavir-ritonavir had HIV RNA levels of <200 copies/ml. No infant was HIV infected. These data are encouraging for the use of this combination for prevention of mother-to-child transmission of HIV.

* Corresponding author. Mailing address: Department of Infectious Diseases, Pitie-Salpetriere Hospital, 47 Boulevard de l'Hôpital, 75013 Paris, France. Phone: 33 1 45 21 27 83. Fax: 33 1 45 21 26 32. E-mail: jade.ghosn{at}bct.aphp.fr

{triangledown} Published ahead of print on 4 February 2008.

Antimicrobial Agents and Chemotherapy, April 2008, p. 1542-1544, Vol. 52, No. 4
0066-4804/08/$08.00+0     doi:10.1128/AAC.01301-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»